United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride 100 mg - ethambutol hydrochloride is indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in-vitro susceptibility studies. in patients who have not received previous antituberculous therapy, i.e., initial treatment, the most frequently used regimens have been the following: - ethambutol plus isoniazid - ethambutol plus isoniazid plus streptomycin. in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in-vitro studies. antituberculous drugs used with ethambutol have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. alternating drug regimens have also been utilized. ethambutol hydrochloride is contraindicated in patients who are known to be hypersensitive to this drug. it is also contraindicated in patients with known optic neuritis unless clinical judgement determines that it may be used. ethambutol hydrochloride is contraindicated in patients who are unable to appreciate and report visual side effects or changes in vision (e.g., young children, unconscious patients).

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride 400 mg - ethambutol hydrochloride tablets usp are indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculous therapy, i.e., initial treatment, the most frequently used regimens have been the following: ethambutol hydrochloride tablets usp plus isoniazid ethambutol hydrochloride tablets usp plus isoniazid plus streptomycin. in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol hydrochloride tablets usp should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial suscept

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride 400 mg - ethambutol hydrochloride tablets are indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculous therapy, i.e., initial treatment, the most frequently used regimens have been the following: ethambutol plus isoniazid ethambutol plus isoniazid plus streptomycin. in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculous drugs

United States - English - NLM (National Library of Medicine)

versapharm incorporated - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride 100 mg - ethambutol hydrochloride tablets, usp are indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculous therapy, i.e., initial treatment, the most frequently used regimens have been the following: ethambutol hydrochloride, usp plus isoniazid ethambutol hydrochloride, usp plus isoniazid plus streptomycin in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol hydrochloride should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been

United States - English - NLM (National Library of Medicine)

american health packaging - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride 400 mg - ethambutol hydrochloride is indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in-vitro susceptibility studies. in patients who have not received previous antituberculous therapy, i.e., initial treatment, the most frequently used regimens have been the following: - ethambutol plus isoniazid - ethambutol plus isoniazid plus streptomycin in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in-vitro studies.

United States - English - NLM (National Library of Medicine)

department of state health services, pharmacy branch - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride 400 mg - ethambutol hci is indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculous therapy, ie, initial treatment, the most frequently used regimens have been the following: - ethambutol hci plus isoniazid - ethambutol hci plus isoniazid plus streptomycin. in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol hci should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculous drugs used w

United States - English - NLM (National Library of Medicine)

sti pharma llc - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride 400 mg - ethambutol hcl is indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculous therapy, ie, initial treatment, the most frequently used regimens have been the following: ethambutol hcl plus isoniazidethambutol hcl plus isoniazid plus streptomycin. in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol hcl should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculous drugs used with ethambutol hcl have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. alternating drug regimens have also been utilized. ethambutol hcl is contraindicated in patients who are known to be hypersensitive to this drug. it is also contraindicated in patients with known optic neuritis unless clinical judgment determines that it may be used. ethambutol hcl is contraindicated in patients who are unable to appreciate and report visual side effects or changes in vision (e.g., young children, unconscious patients).

United States - English - NLM (National Library of Medicine)

sti pharma - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride 400 mg - ethambutol hci is indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculous therapy, ie, initial treatment, the most frequently used regimens have been the following: in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol hci should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculous drugs used with ethambutol hci have included cycloserine, ethionamide, pyrazinamide, viomycin a

United States - English - NLM (National Library of Medicine)

carilion materials management - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride 100 mg - ethambutol hydrochloride is indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in-vitro susceptibility studies. in patients who have not received previous antituberculous therapy, i.e., initial treatment, the most frequently used regimens have been the following: - ethambutol plus isoniazid - ethambutol plus isoniazid plus streptomycin. in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in-vitro studies. antituberculous drugs used

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethambutol hydrochloride, quantity: 400 mg - tablet, film coated - excipient ingredients: ethylcellulose; magnesium stearate; titanium dioxide; polyethylene glycol monomethyl ether; povidone; purified talc; propylene glycol; hypromellose; maize starch; colloidal anhydrous silica - ethambutol lupin is indicated for the treatment of pulmonary tuberculosis, as shown by a large number of studies by investigators throughout the world. it has also been used successfully in cases of primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculous meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculosis of the skin and tuberculous eye diseases. it should not be used as the sole antituberculosis drug, but should be used in conjunction with at least one other antituberculosis drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies.,in patients who have not received previous antituberculosis therapy, i.e. initial treatment, the most frequently used regimens have included three of the following drugs ? ethambutol, isoniazid, rifampicin and streptomycin - for the first 2-4 months. for example:,? ethambutol plus isoniazid plus rifampicin; or ? ethambutol plus isoniazid plus streptomycin,then continuing with a two drug regimen such as,? ethambutol plus isoniazid; or ? ethambutol plus rifampicin.,in patients who have received previous antituberculosis therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment cases ethambutol lupin should be combined with at least one of the second-line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculosis drugs used with ethambutol have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. alternating drug regimens have also been utilised.